Biosimilars Research Pipeline

A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. Biosimilar innovative products are on the rise. The numbers of new drugs seeking approval are growing at a compounded rate of around 5% half early. Almost 1.5 times the number of biosimilars are expected to be in the market in 2017 compared to in the last 5 years.

  • Biotechnology medicinal products for different diseases/disorders
  • Biosimilars for Autoimmune diseases
  • Biosimilars in Dermatological diseases
  • Biosimilar antibodies
  • Biopharmaceuticals development
  • Future of next generation biosimilars

Biosimilars Research Pipeline Conference Speakers

Recommended Sessions

Related Journals

Are you interested in